Opportunities for Nitric Oxide in Potentiating Cancer Immunotherapy

Overview

Journal Pharmacol Rev

Specialty Pharmacology

Date 2022 Sep 30

PMID 36180108

Authors

Jihoon Kim

Susan N Thomas

Affiliations

Soon will be listed here.

Abstract

Despite nearly 30 years of development and recent highlights of nitric oxide (NO) donors and NO delivery systems in anticancer therapy, the limited understanding of exogenous NO's effects on the immune system has prevented their advancement into clinical use. In particular, the effects of exogenously delivered NO differing from that of endogenous NO has obscured how the potential and functions of NO in anticancer therapy may be estimated and exploited despite the accumulating evidence of NO's cancer therapy-potentiating effects on the immune system. After introducing their fundamentals and characteristics, this review discusses the current mechanistic understanding of NO donors and delivery systems in modulating the immunogenicity of cancer cells as well as the differentiation and functions of innate and adaptive immune cells. Lastly, the potential for the complex modulatory effects of NO with the immune system to be leveraged for therapeutic applications is discussed in the context of recent advancements in the implementation of NO delivery systems for anticancer immunotherapy applications. SIGNIFICANCE STATEMENT: Despite a 30-year history and recent highlights of nitric oxide (NO) donors and delivery systems as anticancer therapeutics, their clinical translation has been limited. Increasing evidence of the complex interactions between NO and the immune system has revealed both the potential and hurdles in their clinical translation. This review summarizes the effects of exogenous NO on cancer and immune cells in vitro and elaborates these effects in the context of recent reports exploiting NO delivery systems in vivo in cancer therapy applications.

Citing Articles

Review: Application of Protein-Based Raw Materials in Health Foods in China.

Duan H, Liu G, Liu J, Wang Z, Bao S, Chang X Foods. 2025; 14(1.

PMID: 39796310 PMC: 11720526. DOI: 10.3390/foods14010020.

Nitric oxide facilitates the S-nitrosylation and deubiquitination of Notch1 protein to maintain cancer stem cells in human NSCLC.

Zhang T, Lei J, Zheng M, Wen Z, Zhou J J Cell Mol Med. 2024; 28(21):e70203.

PMID: 39523215 PMC: 11550923. DOI: 10.1111/jcmm.70203.

Nitric oxide-based multi-synergistic nanomedicine: an emerging therapeutic for anticancer.

Tang Y, Li Q, Zhou Z, Bai H, Xiao N, Xie J J Nanobiotechnology. 2024; 22(1):674.

PMID: 39497134 PMC: 11536969. DOI: 10.1186/s12951-024-02929-z.

Challenging the Norm: The Unrecognized Impact of Soluble Guanylyl Cyclase Subunits in Cancer.

Pino M, Rocca M, Acosta L, Cabilla J Int J Mol Sci. 2024; 25(18).

PMID: 39337539 PMC: 11432225. DOI: 10.3390/ijms251810053.

Neutrophil-Targeting Semiconducting Polymer Nanotheranostics for NIR-II Fluorescence Imaging-Guided Photothermal-NO-Immunotherapy of Orthotopic Glioblastoma.

Liu J, Cheng D, Zhu A, Ding M, Yu N, Li J Adv Sci (Weinh). 2024; 11(39):e2406750.

PMID: 39159216 PMC: 11497063. DOI: 10.1002/advs.202406750.

References

NEEDLEMAN P, KRANTZ Jr J . The biotransformation of nitroglycerin. Biochem Pharmacol. 1965; 14(8):1225-30. DOI: 10.1016/0006-2952(65)90299-6. View

Hasan N, Lee J, Kwak D, Kim H, Saparbayeva A, Ahn H . Diethylenetriamine/NONOate-doped alginate hydrogel with sustained nitric oxide release and minimal toxicity to accelerate healing of MRSA-infected wounds. Carbohydr Polym. 2021; 270:118387. DOI: 10.1016/j.carbpol.2021.118387. View

Katritzky A, Khashab N, Kirichenko N, Singh A . Microwave-assisted preparations of amidrazones and amidoximes. J Org Chem. 2006; 71(24):9051-6. DOI: 10.1021/jo061410u. View

Shin D, Ribas A . The evolution of checkpoint blockade as a cancer therapy: what's here, what's next?. Curr Opin Immunol. 2015; 33:23-35. DOI: 10.1016/j.coi.2015.01.006. View

Wculek S, Cueto F, Mujal A, Melero I, Krummel M, Sancho D . Dendritic cells in cancer immunology and immunotherapy. Nat Rev Immunol. 2019; 20(1):7-24. DOI: 10.1038/s41577-019-0210-z. View

Bogdan C . Nitric oxide and the immune response. Nat Immunol. 2001; 2(10):907-16. DOI: 10.1038/ni1001-907. View

Kim J, Francis D, Sestito L, Archer P, Manspeaker M, OMelia M . Thermosensitive hydrogel releasing nitric oxide donor and anti-CTLA-4 micelles for anti-tumor immunotherapy. Nat Commun. 2022; 13(1):1479. PMC: 8933465. DOI: 10.1038/s41467-022-29121-x. View

Tumurkhuu G, Koide N, Dagvadorj J, Noman A, Khuda I, Naiki Y . B1 cells produce nitric oxide in response to a series of toll-like receptor ligands. Cell Immunol. 2009; 261(2):122-7. DOI: 10.1016/j.cellimm.2009.11.009. View

Chakrapani H, Goodblatt M, Udupi V, Malaviya S, Shami P, Keefer L . Synthesis and in vitro anti-leukemic activity of structural analogues of JS-K, an anti-cancer lead compound. Bioorg Med Chem Lett. 2008; 18(3):950-3. PMC: 2278236. DOI: 10.1016/j.bmcl.2007.12.044. View

10.

Liano D, HayGlass K, Benacerraf B, Sy M, Abbas A . The role of antigen-presenting B cells in T cell priming in vivo. Studies of B cell-deficient mice. J Immunol. 1988; 140(11):3773-8. View

11.

Chen X, Shao Q, Hao S, Zhao Z, Wang Y, Guo X . CTLA-4 positive breast cancer cells suppress dendritic cells maturation and function. Oncotarget. 2017; 8(8):13703-13715. PMC: 5355131. DOI: 10.18632/oncotarget.14626. View

12.

Si C, Zhang R, Wu T, Lu G, Hu Y, Zhang H . Dendritic cell-derived nitric oxide inhibits the differentiation of effector dendritic cells. Oncotarget. 2016; 7(46):74834-74845. PMC: 5342705. DOI: 10.18632/oncotarget.11361. View

13.

Ding Y, Du C, Qian J, Dong C . NIR-Responsive Polypeptide Nanocomposite Generates NO Gas, Mild Photothermia, and Chemotherapy to Reverse Multidrug-Resistant Cancer. Nano Lett. 2019; 19(7):4362-4370. DOI: 10.1021/acs.nanolett.9b00975. View

14.

Sharma A, Muresanu D, Patnaik R, Sharma H . Size- and age-dependent neurotoxicity of engineered metal nanoparticles in rats. Mol Neurobiol. 2013; 48(2):386-96. DOI: 10.1007/s12035-013-8500-0. View

15.

Ghezzi P . Role of glutathione in immunity and inflammation in the lung. Int J Gen Med. 2011; 4:105-13. PMC: 3048347. DOI: 10.2147/IJGM.S15618. View

16.

Allione A, Bernabei P, Bosticardo M, Ariotti S, Forni G, Novelli F . Nitric oxide suppresses human T lymphocyte proliferation through IFN-gamma-dependent and IFN-gamma-independent induction of apoptosis. J Immunol. 1999; 163(8):4182-91. View

17.

Hirano K, Hosoi A, Matsushita H, Iino T, Ueha S, Matsushima K . The nitric oxide radical scavenger carboxy-PTIO reduces the immunosuppressive activity of myeloid-derived suppressor cells and potentiates the antitumor activity of adoptive cytotoxic T lymphocyte immunotherapy. Oncoimmunology. 2015; 4(8):e1019195. PMC: 4570109. DOI: 10.1080/2162402X.2015.1019195. View

18.

Dong X, Liu H, Feng H, Yang S, Liu X, Lai X . Enhanced Drug Delivery by Nanoscale Integration of a Nitric Oxide Donor To Induce Tumor Collagen Depletion. Nano Lett. 2019; 19(2):997-1008. DOI: 10.1021/acs.nanolett.8b04236. View

19.

Siddiqui S, Alatery A, Kus A, Basta S . TLR engagement prior to virus infection influences MHC-I antigen presentation in an epitope-dependent manner as a result of nitric oxide release. J Leukoc Biol. 2010; 89(3):457-68. DOI: 10.1189/jlb.0610357. View

20.

Reynolds M, Saavedra J, Showalter B, Valdez C, Shanklin A, Oh B . Tailored Synthesis of Nitric Oxide-Releasing Polyurethanes Using O-Protected Diazeniumdiolated Chain Extenders. J Mater Chem. 2010; 20(15):3107-2114. PMC: 2994584. DOI: 10.1039/c000152j. View